International Society for Cell & Gene Therapy Launches New Fellowship Program for Clinical Applications

The International Society for Cell & Gene Therapy (ISCT) has taken a significant step in advancing the field of cell and gene therapies (CGT) by introducing its very first Clinical Applications Program tailored for clinical fellows. Scheduled to commence on October 26-27, 2026, this innovative initiative will be held at the University of Pennsylvania, aimed at equipping the next generation of healthcare leaders with the necessary skills and knowledge to implement CGT in clinical settings.

As CGT therapies continue to receive regulatory approvals at an increasing rate, the demand for trained clinicians is growing. This program serves a dual purpose according to Queenie Jang, CEO of ISCT: not only will it provide invaluable education to fellows destined to become future leaders in the field, but it will also build connections within the clinical CGT community.

The inaugural class will feature a selective group of clinical fellows predominantly from the United States and Canada, focusing on complex applications of CGT in areas such as hematology/oncology, transplantation, and immune-mediated conditions, including rheumatological disorders. Such a concentrated program underscores ISCT's commitment to fostering clinical excellence in the field of CGT, enhancing the quality of patient care.

Key figures leading this initiative include Dr. Miguel Forte, the President of ISCT, who emphasizes the urgent need to invest in clinician education as the approval of CGTs accelerates. He underlined that this program is critical for translating scientific advancements into practical healthcare solutions that can ultimately benefit patients.

The curriculum is designed to offer a structured immersion into clinical best practices, operational strategies, and the latest developments in CGT therapies. Participants will also benefit from direct access to a global network of experts who are shaping the CGT landscape, thereby enriching their learning experience.

Each session of the fellowship is expected to be co-chaired by prominent figures in the field, including Dr. Jaap Jan Boelens, Regional Vice President of ISCT for North America and Chief of Transplantation and Cellular Therapies at Memorial Sloan Kettering Cancer Center, along with Dr. Alice Bertaina, a Board member of ISCT and the Section Chief of Stem Cell Transplant and Regenerative Medicine at Stanford University. The mentorship provided through this program offers a unique opportunity for the next wave of clinicians to learn from established leaders in CGT.

This groundbreaking program is viewed as an essential step toward establishing a robust, global clinical community ready to deploy CGT innovations effectively. It is designed not only to prepare clinicians for the technical aspects of cell and gene therapies but also to foster a sense of collective purpose and collaboration as they navigate the complexities of implementing these therapies across diverse medical systems.

For those interested in applying for this unique fellowship, further details, including faculty information and application procedures, can be accessed on the ISCT Institute of Training & Development’s website. This program represents a vital investment in the future of CGT, ensuring that the healthcare community is equipped to bring these life-saving treatments to patients worldwide.

Founded in 1992, the ISCT aims to be at the forefront of cell and gene therapy efforts, uniting clinicians, researchers, and industry leaders who seek to transform theoretical innovations into practical solutions that enhance patients' quality of life. Through collaborative initiatives like this, the ISCT signifies a commitment to not only advancing technical knowledge in the field but also solidifying the bonds among practitioners dedicated to improving health outcomes in diverse populations.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.